Avanir gains rights to Concert's 'heavy' Nuedexta dextromethorphan
This article was originally published in Scrip
Executive Summary
Concert Pharmaceuticals has forged a pact with Avanir, whereby Avanir gains global rights to develop and commercialise experimental, deuterium-modified dextromethorphan compounds. Avanir plans to develop the compounds – still in the preclinical stage – for the potential treatment of neurological and psychiatric disorders.